News releases from Agendia
Agendia to Participate in 2020 Canaccord Genuity Virtual MedTech & Diagnostics Forum
November 05, 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Canaccord Genuity Virtual MedTech & Diagnostics Forum, which takes place November...
Agendia Co-Founder Named to Eighth Annual OncLive® Giants of Cancer Care® Class of Inductees
October 28, 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that co-founder and Chief Research Officer Laura van 't Veer, PhD, will be inducted as this year's Cancer...
MammaPrint® Approved for Reimbursement in Germany
October 21, 2020
Agendia Inc., a world leader in precision oncology for breast cancer, announced today that the Federal Joint Committee (G-BA) has approved MammaPrint® , Agendia's 70-Gene Breast Cancer Recurrence...
Agendia to Participate in Stifel 2020 Virtual Healthcare Conference
October 15, 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Stifel Virtual Healthcare Conference, which takes place November 16-18, 2020....
Agendia Presents New Data Demonstrating Clinical Utility for MammaPrint and BluePrint at the 2020 European Breast Cancer Conference Virtual Event
October 02, 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the presentation of four studies at the 12th European Breast Cancer Conference (EBCC-12). The data include a...
In celebration of Breast Cancer Awareness Month, Agendia, Inc., a world leader in precision oncology for breast cancer, is proud to present the I AM HERE campaign, a collection of illustrations and...
Agendia Presents New Data Demonstrating MammaPrint's Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress
September 17, 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 showing that MammaPrint's Ultra-Low...
Agendia to Showcase New Data at the European Society for Medical Oncology Virtual Congress 2020
September 14, 2020
Inc. Magazine Unveils Its Annual List of America's Fastest-Growing Private Companies--the Inc. 5000
August 14, 2020
This week, Inc. magazine revealed that Agendia, Inc. has been included on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies. The list represents...
Agendia Expands Management Team to Meet Company Momentum, Appoints Brian Dow as Chief Financial Officer
July 29, 2020
Chief Operating Officer Kurt Becker to Take on Broadened Role Overseeing Global Operations and Research and Development
Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology
July 27, 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the publication of MINDACT trial data in the July 27 issue of Communications Biology, a Nature Publishers Journal....
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
May 29, 2020
Presentations outline how BluePrint® genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients' benefit
Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint™
May 29, 2020
Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations
May 14, 2020
Data adds to the growing body of evidence demonstrating the efficacy of Agendia's MammaPrint® and BluePrint® testing to consistently inform optimal breast cancer treatment planning
Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
May 07, 2020
- Development of MammaPrint®, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
April 16, 2020
Agendia®, Inc., a world leader in precision oncology for breast cancer, announced today that Translational Cancer published long term analytical performance characteristics of the 80-gene BluePrint®...
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
February 18, 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that BMC Cancer published results from the IMPACt trial. The study measured changes in both treatment decisions...
Laura van 't Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
January 17, 2020
Laura van 't Veer, Ph.D., co-founder of Agendia Inc. and developer of MammaPrint, the 70-gene risk of recurrence assay for breast cancer patients, will be recognized by Precision Medicine World...
Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse
January 03, 2020
Agendia Inc., a world leader in precision oncology for breast cancer, announces that one of the largest healthcare insurers in Germany, Techniker Krankenkasse, has joined the Selective Contract of the...
New Data Compare Genomic Profiling Results for Premenopausal Women with Early-Stage Breast Cancer
December 12, 2019
Agendia, Inc., a world leader in precision oncology for breast cancer, announced today new data comparing genomic profiling results for patients under the age of 50 with early-stage breast cancer. The...
Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
November 19, 2019
Data evaluating MammaPrint® and BluePrint® includes new risk analysis of premenopausal women with breast cancer, and insights into unique characteristics among specific populations of breast cancer...
Agendia: Key Studies Presented at the San Antonio Breast Cancer Symposium Demonstrate the Important Role of MammaPrint® for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients
December 12, 2017
Agendia, Inc. announces findings of three studies presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) last week.
Agendia and UZ Leuven Partner to Co-Validate MammaPrint® BluePrint® Breast Cancer Risk of Recurrence and Molecular Subtyping Kit Ahead of European Launch
December 06, 2017
Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and University Hospitals Leuven (UZ Leuven) in Belgium have partnered to co-validate Agendia’s new in vitro diagnostic...
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint® BluePrint® Breast Cancer Kit Co-Validation Study
December 04, 2017
Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and Institute Curie in Paris, France, a leading player in the fight against cancer, announce a co-validation...
Agendia: New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint® and BluePrint® Across Breast Cancer Patient Populations
November 30, 2017
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Cancer Symposium...
Agendia’s MammaPrint® Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code
November 28, 2017
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test has received a favorable payment...
AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update
November 20, 2017
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Joint Committee on Cancer (AJCC) has recently issued a Breast Cancer Update and...
New Study Published in JAMA Oncology Shows MammaPrint® Changed Breast Cancer Treatment Decisions in 3 out of 4 Cases where Guidance was Unclear with the 21-Gene Assay
October 26, 2017
New data published in JAMA Oncology shows MammaPrint® changes treatment decisions for patients who previously received an ‘intermediate’ risk result
Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data
July 10, 2017
Agendia announces ASCO has published revised early-stage breast cancer guidelines in the Journal of Clinical Oncology, highlighting use of MammaPrint